# US 8,148,091 B2 · Detection of chronic kidney disease patients or coronary artery disease using bone morphogenic protein-4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,148,091 B2
- Document ID: US8148091B2
- Status: Granted
- Kind: B2
- Application number: 13/009,428
- Filed: 2011-01-19
- Published: 2011-05-19
- Granted: 2012-04-03
- Earliest claimed: 2006-10-13
- Assignees: Ochsner Clinic Foundation
- Inventors: Thomas Cooper Woods; Corey Keith Goldman
- Web page: https://patentgrep.com/patent/US8148091B2

## CPC

- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2333/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

## Claims

### Claim 1

A method comprising the steps of assaying a serum or plasma sample of a human patient for BMP-4 levels and diagnosing the presence of CAD when said BMP-4 levels are above 100 pg/mL.

### Claim 2 (depends on 1)

The method of claim 1 wherein said BMP-4 levels are above about 105 pg/mL.

### Claim 3

A method comprising the steps of assaying a serum or plasma sample of a human patient for BMP-4 levels and diagnosing the presence of CAD and CKD when said BMP-4 levels are greater than 105 pg/mL.

### Claim 4 (depends on 3)

The method of claim 3 further including the step of assaying said serum or plasma sample of said human patient for creatinine levels and confirming the presence of CAD and CKD when said creatinine levels are greater than 1.4 mg/dL for a male patient or above 1.2 mg/dL for a female patient.

### Claim 5

A method comprising the steps of assaying a serum or plasma sample of a human patient for BMP-4 levels and diagnosing the absence of CAD when said BMP-4 levels are less than 100 pg/mL.

### Claim 6 (depends on 5)

The method of claim 5 wherein said BMP-4 levels are less than about 75 pg/mL.

### Claim 7 (depends on 5)

The method of claim 5 further including the step of assaying said serum or plasma sample of said human patient for creatinine levels and diagnosing the absence of CKD when said creatinine levels are less than 1.4 mg/dL for a male patient or less than 1.2 mg/dL for a female patient.

### Claim 8

A method comprising the steps of assaying a serum or plasma sample of a human patient for BMP-4 levels and diagnosing the absence of CAD and CKD when said BMP-4 levels are less than 100 pg/mL, said method further including the step of assaying said serum or plasma sample of said human patient for creatinine levels and confirming the absence of CAD and CKD when said creatinine levels are less than 1.4 mg/dL for a male patient or less than 1.2 mg/dL for a female patient.